Pacific Edge raises NZ$25.4M in upsized placement

Cancer diagnostics firm Pacific Edge (ASX:PEB) has capitalised on investor appetite, announcing an upsized NZ$25.4 million equity placement.

The Dunedin-based company originally sought a smaller injection but expanded the offer following oversubscriptions from institutional and private investors.

Completed on May 12, the placement was priced at NZ$0.17 per share, representing a modest 2.3% discount to the closing price recorded on May 8.

The capital influx is strategically earmarked to bolster the company’s push for Medicare re-coverage in the United States—a critical hurdle for the broader adoption of its bladder-cancer diagnostic tests.

Chief Executive Dr Peter Meintjes emphasised that emerging clinical evidence is rapidly shifting sentiment in favour of the company’s technology within the Asia Pacific and US regions.

To ensure equitable participation, Pacific Edge will launch a NZ$6 million retail offer for existing shareholders on May 14, maintained at the same NZ$0.17 entry price.

Advised by Cameron Partners and Harmos Horton Lusk, the company intends to use these combined resources to accelerate product development and maintain momentum in evidence generation.

The raising underscores market confidence in Pacific Edge’s clinical roadmap as it seeks to institutionalise its diagnostic tools within commercial payer networks worldwide.

At the time of reporting, Pacific Edge’s share price was $0.14.